Demonstration Formulary
3 Respiratory system
03-11 Antifibrotics
| Nintedanib Ofev® |
|
Restricted
|
Hospital only- NHSE commissioned In line with NICE and available from day 91 following publication of TA |
 NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
|
| Nintedanib Vargatef® |
|
Formulary
|
Hospital ONLY NHSE comissioned In line with NICE and available from day 91 following publication of TA |
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
|
| Pirfenidone Esbriet® |
|
Restricted
|
Hospital only - NHSE commissioned |
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
|
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
- NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
- NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases